Notably, PPARα induces FALDH expression [64] and the PPARα agonist Bezafibrate has been suggested as an agent for treating Sjögren-Larsson Syndrome patients with partially inactivated FALDH [65]. Here, ALDH3A2 is linked to Sjögren-Larsson syndrome.